이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
ACADIA Pharmaceuticals 관리
관리 기준 확인 4/4
현재 CEO에 대한 정보가 충분하지 않습니다.
주요 정보
Steve Davis
최고 경영자
US$7.6m
총 보상
| CEO 급여 비율 | 11.3% |
| CEO 임기 | 9yrs |
| CEO 소유권 | 0.1% |
| 경영진 평균 재임 기간 | 2.7yrs |
| 이사회 평균 재임 기간 | 8.9yrs |
최근 관리 업데이트
Recent updates
Acadia Pharmaceuticals: Nuplazid Performs In Q2 While Daybue Disappoints Again
Aug 26The Strong Earnings Posted By ACADIA Pharmaceuticals (NASDAQ:ACAD) Are A Good Indication Of The Strength Of The Business
Aug 14
ACADIA Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 09ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking
Aug 01Shareholders Will Probably Hold Off On Increasing ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Compensation For The Time Being
May 23ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking
Apr 24We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Mar 27Acadia Pharmaceuticals: Post Pimavanserin Study Setback Selloff May Continue
Mar 12ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Just Released Its Full-Year Earnings: Here's What Analysts Think
Mar 01Acadia Pharmaceuticals: New Daybue Drug Already Showing Signs Of Slowing
Feb 29Soleno Therapeutics And Acadia Pharmaceuticals: Hope For Prader-Willi Families
Jan 23ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Share Price Boosted 35% But Its Business Prospects Need A Lift Too
Jan 03We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Dec 04Insufficient Growth At ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Hampers Share Price
May 22Acadia Pharmaceuticals: Nuplazid's (Pimavanserin) Last Hurrah
Oct 19FDA accepts Acadia's new drug application for Rett syndrome treatment trofinetide
Sep 12Acadia: Powerful Unfolding Catalysts
Aug 03Acadia Pharma submits marketing application to FDA for trofinetide to treat Rett syndrome
Jul 18FDA AdComm Rejects Nuplazid This Time But Acadia's Race Isn't Run Yet
Jun 29Companies Like ACADIA Pharmaceuticals (NASDAQ:ACAD) Can Afford To Invest In Growth
May 07CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$31m |
| Mar 31 2024 | n/a | n/a | -US$2m |
| Dec 31 2023 | US$8m | US$857k | -US$61m |
| Sep 30 2023 | n/a | n/a | -US$149m |
| Jun 30 2023 | n/a | n/a | -US$111m |
| Mar 31 2023 | n/a | n/a | -US$146m |
| Dec 31 2022 | US$14m | US$822k | -US$216m |
| Sep 30 2022 | n/a | n/a | -US$217m |
| Jun 30 2022 | n/a | n/a | -US$205m |
| Mar 31 2022 | n/a | n/a | -US$214m |
| Dec 31 2021 | US$10m | US$793k | -US$168m |
| Sep 30 2021 | n/a | n/a | -US$192m |
| Jun 30 2021 | n/a | n/a | -US$262m |
| Mar 31 2021 | n/a | n/a | -US$260m |
| Dec 31 2020 | US$8m | US$768k | -US$282m |
| Sep 30 2020 | n/a | n/a | -US$268m |
| Jun 30 2020 | n/a | n/a | -US$225m |
| Mar 31 2020 | n/a | n/a | -US$238m |
| Dec 31 2019 | US$8m | US$744k | -US$235m |
| Sep 30 2019 | n/a | n/a | -US$248m |
| Jun 30 2019 | n/a | n/a | -US$268m |
| Mar 31 2019 | n/a | n/a | -US$276m |
| Dec 31 2018 | US$7m | US$720k | -US$245m |
| Sep 30 2018 | n/a | n/a | -US$249m |
| Jun 30 2018 | n/a | n/a | -US$252m |
| Mar 31 2018 | n/a | n/a | -US$256m |
| Dec 31 2017 | US$15m | US$700k | -US$289m |
보상 대 시장: Steve 의 총 보상 ($USD 7.59M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 6.80M ).
보상과 수익: Steve 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.
CEO
Steve Davis (63 yo)
9yrs
테뉴어
US$7,587,014
보상
Mr. Stephen R. Davis, also known as Steve, J. D. served as the Director at Heron Therapeutics Inc. since September 2019 until February 21, 2023. He has been the Chief Executive Officer of ACADIA Pharmaceut...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| President | 9yrs | US$7.59m | 0.11% $ 2.9m | |
| Executive VP & CFO | 3yrs | US$2.59m | 0.026% $ 677.1k | |
| Executive VP | 2.8yrs | US$2.62m | 0.031% $ 807.8k | |
| VP, Chief Accounting Officer & Corporate Controller | 4.1yrs | 데이터 없음 | 0.0087% $ 222.4k | |
| Executive VP and Head of Research & Development | less than a year | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Technical Development & Operations | 1.8yrs | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Investor Relations & Corporate Communications | less than a year | 데이터 없음 | 데이터 없음 | |
| Executive VP | less than a year | 데이터 없음 | 데이터 없음 | |
| Senior VP & Head of Sales | 2.7yrs | 데이터 없음 | 데이터 없음 | |
| Senior VP & Chief People Officer | 2.7yrs | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of New Product Planning & Strategy | no data | 데이터 없음 | 데이터 없음 | |
| SVP, Global Head of Medical Affairs & Chief Medical Officer | 4.8yrs | 데이터 없음 | 데이터 없음 |
2.7yrs
평균 재임 기간
52yo
평균 연령
경험이 풍부한 관리: ACAD 의 관리팀은 경험 ( 2.4 년 평균 재직 기간)으로 간주됩니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| President | 9yrs | US$7.59m | 0.11% $ 2.9m | |
| Independent Director | 16.3yrs | US$392.75k | 0.012% $ 312.0k | |
| Independent Director | 8.8yrs | US$377.75k | 0.062% $ 1.6m | |
| Member of the Scientific and Clinical Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Independent Director | 8.8yrs | US$387.75k | 0.015% $ 397.2k | |
| Independent Director | 9.5yrs | US$387.75k | 0.021% $ 536.4k | |
| Member of the Scientific and Clinical Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of the Scientific and Clinical Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of the Scientific and Clinical Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Independent Director | 8.7yrs | US$387.75k | 0.015% $ 381.6k | |
| Independent Chairman of the Board | 11.7yrs | US$432.75k | 0.062% $ 1.6m | |
| Independent Director | 4yrs | US$377.75k | 0.014% $ 348.4k |
8.9yrs
평균 재임 기간
66yo
평균 연령
경험이 풍부한 이사회: ACAD 의 이사회는 경험(평균 재직 기간 8.7 년)으로 간주됩니다.